



CABA

# 2013 CABA Biomedical Investment & Entrepreneurship Symposium

2013 美中生物医药协会生物医药投资与创业研讨会

Saturday, October 19, 2013

9:00 AM – 5:30 PM

The Doubletree Guest Suites, Boston, MA



*Opportunities for Biomedical Investors and Entrepreneurs*

[WWW.CABAWEB.ORG](http://WWW.CABAWEB.ORG)



CABA

Chinese-American BioMedical Association

美中生物医药协会



## 2013 CABA Biomedical Investment & Entrepreneurship Symposium

### 2013 美中生物医药协会生物医药投资与创业研讨会

#### Presented by

Chinese-American BioMedical Association (CABA)

9:00 AM –5:30 PM

Saturday, October 19, 2013

The Doubletree Guest Suites, Boston MA

400 Soldiers Field Road, Boston, MA 02134

#### Admission

CABA members: FREE; Non-members: \$30. On-site membership registration to CABA available (\$30 annual membership fee due). You can also register online at [www.cabaweb.org](http://www.cabaweb.org).

#### Driving Direction & Parking

Please enter the hotel parking garage from Storrow Drive. Parking is **free**.

#### Symposium Organizing Committee

Zhigang Wang  
Charles Wu  
Fang Liu

Youxin Zhang  
Gwen Ren  
Carrie Liu

Ji Shi  
Kun Liu  
Yikai Wang

Liping Zhou  
Ying Dong  
Jo Lee

*For information about CABA and upcoming events, please check CABA Web site:  
[www.cabaweb.org](http://www.cabaweb.org).*

## Program

- 8:30am - 9:00am: Registration
- 9:00am - 9:10am: Opening Remark  
**Xiang Yang Yu**, President, CABA
- 9:10am - 10:45am: Plenary Session I, **TBD**, Chair  
9:15 to 9:45am: **Amir Nashat**, Polaris Venture Partners (Keynote)  
Investing in Early Stage Innovation and Biotech  
9:45 to 10:15am: **Jason Wen**, Boston College  
University Start-Up  
10:15 to 10:45am: **Yugui Gu**, Cubist Pharmaceuticals, Inc.  
Increasing Role of External Research in Drug Discovery at Cubist
- 10:45am to 11:00am: Coffee Break
- 11:00am to 12:00pm: Panel Discussion - VC  
Moderator, **Jonathan Fleming**, Oxford Bioscience Partners and  
MIT Sloan School of Management  
**David Xie**, Oliver Wyman  
**Katherine Bowdish**, Sanofi and Head of Sunrise  
**Linda Ji**, Nixon Peabody  
**Xin Huang**, Suzhou Cowin Venture Capital  
**Ting Xu**, Alphamab
- 12:00pm to 1:15pm: Lunch Break
- 12:15pm to 1:00pm: Workshop on Investing for Retirement led by **Gwen Ren**, Morgan Stanley
- 1:15pm to 2:45pm: Plenary Session II, **Allen Che**, Chair  
1:15 to 1:45pm: **Jack Liu**, Morgan Stanley (Keynote)  
Medical Technology Key Investment Themes  
1:45 to 2:15pm: **Jinbo Lee**, Scilligence Corporation  
Fulfill Unmet Needs of New Pharma/Biotech R&D Models: The Scilligence  
Story  
2:15 to 2:45pm: **Weiwen Ying**, Synta Pharmaceuticals Group  
HDC (Hsp90-Inhibitor Drug Conjugates): An Exciting and New Platform  
Technology in Oncology Drug Development
- 2:45pm to 3:00pm: Coffee Break
- 3:00am to 4:00pm: Panel Discussion - CRO  
Moderator, **Deqiang Niu**, Celgene Avilomics Research, Inc.  
**Taiping Chen**, Ph.D., Vivo Biotech Ltd.

**George Shi**, Anichem

**Mohan Thiruvazhi**, GVK BIO

**Tiansheng Wang**, Vertex Pharmaceuticals, Inc.

**Libing Yu**, Alputon

**Sherry Yu**, Sundia MediTech

**Jin Zhao**, Genzyme

4:00am to 5:30pm: Networking Reception sponsored by Trade Star Investment

5:30pm to 9:00pm: Speaker and VIP Dinner

## **Speaker Profiles**

**Amir Nashat, Ph.D.**

Managing Partner, Polaris Venture Partners, Boston, MA

Amir is a managing partner in Polaris' Boston office. He joined Polaris in April 2002 and focuses on investments in healthcare, consumer products and energy.

Amir currently represents Polaris as a Director of AgBiome, aTyr Pharmaceuticals, BIND Therapeutics (NASDAQ: BIND), Fate Therapeutics, Promedior Pharmaceuticals, Receptos (NASDAQ: RCPT), Scholar Rock, Selecta Biosciences and Sun Catalytix. Additionally, Amir has served as a Director of Adnexus Therapeutics (acquired by Bristol Myers Squibb), Athenix Corporation (acquired by Bayer), Avila Therapeutics (acquired by Celgene), Living Proof, Pervasis Therapeutics (acquired by Shire Pharmaceuticals) and served as a Board Observer of GI Dynamics (GID.AX). In addition to his role as an investor, Amir has also served as the initial CEO of Living Proof (known as Andora at the time), and Sun Catalytix Corporation.

Prior to joining Polaris, Amir completed his PhD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.

Amir serves on the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT. He previously served on the Board of the New England Venture Capital Association. He has been named to the Forbes Midas list of Top 100 Venture Capitalists.

**Presentation Title:** Investing in Early Stage Innovation and Biotech

**Abstract:** Important discoveries and profound innovations are the hallmark of the biotechnology industry. In the past few years, a number of important medicines have emerged from the biotechnology industry and made a significant impact on human health. Despite the great contributions, our industry faces significant headwinds, including a scarcity of capital, pipeline pressure within big pharma, and the increasing focus on cost. In this session, we will discuss the various options available to finance cutting edge advances in our field.

**Jason Wen, Ph.D., MBA, CLP, RTTP**

Director of Technology Transfer & Licensing, Boston College, Chestnut Hill, MA

Jason has a strong background combining experience in Life Science, Business and Patent Law, and has more than ten years technology development experience in field of technology transfer/licensing with academic institutions and a biopharmaceutical company. He has been working in the Office of Technology Transfer at Cold Spring Harbor Laboratory as an Assistant Director for more than eight years. As a former Assistant Professor in Virginia Commonwealth University, Dr. Wen has more than ten years scientific research experience with high level of knowledge in biomedical science. He graduated from Nankai University in China and holds a Ph.D. degree in Molecular Biology, MBA degree

from University of Richmond, and finished one year law school studies in a J.D. program. Dr. Wen is a long time member of Association of University Technology Manager (AUTM) and Licensing Executives Society (LES). He was among the first who earned the Certified Licensing Professional (CLP) credential, a current CLP Exam Development Committee member, and he is also a Registered Technology Transfer Professional (RTTP). As a United State Patent and Trademark Office Registered Patent Agent, Dr. Wen has extensive experience in patent application and prosecution. As an active speaker, Dr. Wen has been invited by related Institutions and Associations including as a Venture Forum Business Plan judge and a speaker in 2013 AUTM Annual meeting. Additionally, He has interest in doing tech transfer related business in China. Accordingly, he has been invited to give presentations/training to related societies and top universities/institutions in China with providing consultancy to several biotech companies in the past. He is the first one who formally opened tech transfer class by teaching a new course on “Technology Commercialization” in a top university in China.

**Presentation Title:** University Start-Up

**Abstract:** As an entrepreneur, you are looking for business opportunities including technologies from universities and research institutions. For your Start-Up, how to get an Option or Exclusive License from universities or institutions, how to get investment from VC/angel investment/friends/government, and how to work with inventors from universities. You will hear from Dr. Wen about option and licensing terms for a Start-Up, funding opportunities, service or product development during this session.



**Yugui Gu, Ph. D.**

Head of External Research, Cubist Pharmaceuticals, Inc., Lexington, MA

Yugui has 20 years of drug discovery experience in pharma and biotech. He was Director of Medical Chemistry and is currently Head of External Research at Cubist, responsible for overall external research strategy and management. In addition, he also leads multidisciplinary discovery project team, manages antibacterial medicinal chemistry and oversees exploratory project creation for early discovery pipeline.

Prior to joining Cubist in 2007, Yugui worked in Global Pharmaceutical Discovery at Abbott laboratories for 14 years, where he was Senior Group Leader managing a team of 10-15 chemists and led project team working in multiple therapeutic areas. Yugui’s research interest spans antibacterial, antiviral, pain management, central nervous system, inflammation, diabetes and obesity. He advanced several development candidates to clinic. Yugui authored and co-authored nearly 80 publications. He obtained his PhD from West Virginia University in 1991 followed by two year postdoc research at Indiana University in Bloomington before joining Abbott Laboratories.

**Presentation Title:** Increasing Role of External Research in Drug Discovery at Cubist

**Jack Liu, MBA**

Senior Vice President, Financial Advisor, Morgan Stanley Global Wealth Management Group, New York, NY

Jack has more than twenty year's money management experience. By adopting holistic approaches, he is specialized in tailoring investment portfolios for high-net-worth individuals and institutions. While leveraging Morgan Stanley resources, he follows and analyzes different industry sectors in order to identify investment opportunities. His clients are located around the world; many of them are in Asia. He is also the International Client Advisor at Morgan Stanley, a designation for advisors who can advise non-us investors.

Jack was employed by the National Commission of Science and Technology as a program manager in China. Since he came to the US in the early 90's, he has held senior positions at Merrill Lynch, Citigroup, and HSBC Securities USA. His education includes Dartmouth College, New York Institute of Technology where he earned his MBA.

**Presentation Title:** Medical Technology Key Investment Themes

**Jinbo Lee, Ph.D.**

Co-founder and Chief Scientific Officer of Scilligence Corporation, Burlington, MA

Jinbo is the co-founder and Chief Scientific Officer of Scilligence Corporation. He has extensive experience in drug discovery and development in both pharmaceutical and biotech companies with senior leadership positions. Most recently as the Head of Chemistry at Ensemble Therapeutics, he was responsible for molecule modeling/cheminformatics, medicinal chemistry, process chemistry, and analytical chemistry. Prior to Ensemble Discovery, Dr. Lee led multi-discipline teams including medicinal chemists, X-ray crystallographers, molecular modelers, pharmacologists and DMPK scientists at Wyeth Pharmaceuticals. He has also worked at Boehringer Ingelheim Pharmaceuticals in the areas of medicinal chemistry, combinatorial chemistry and parallel synthesis. Dr. Lee has in-depth knowledge in multiple diseases areas including oncology, metabolic diseases, neurodegenerative diseases, infectious diseases, and inflammatory and autoimmune diseases. He is an expert in research informatics, medicinal chemistry, structure-based drug design and prodrug design. Dr. Lee received his Ph.D. degree in Organic Chemistry from Princeton University. He was the year 1997 recipient of Roche Award for Excellence in Organic Chemistry. Dr. Lee has many publications in prestigious scientific journals and holds a number of patent/patent applications. He has been an invited speaker in numerous drug discovery and scientific conferences.

**Presentation Title:** Fulfill Unmet Needs of New Pharma/Biotech R&D Models: The Scilligence Story

**Abstract:** With prevalence of cross-organization collaborations, R&D reorganizations and biotech company virtualization, how to manage information flow and protect IP has become a new challenge for drug discovery R&D. In this talk, the entrepreneur story of Scilligence to fulfill unmet informatics needs of new R&D model will be shared.



**Weiwen Ying, Ph.D.**

Synta Fellow, Synta Pharmaceuticals Group, Lexington, MA

Weiwen is Synta Fellow at Synta Pharmaceuticals. He initiated and championed the discovery and development of ganetespib, an Hsp90 inhibitor, which is being evaluated in multiple clinical trials including a Phase III trial in lung cancer. As a prolific drug hunter, his experience in drug development ranges from conception of scientific ideas to managing relations with physicians and academic collaborators. Dr. Ying has published >20 peer-review journal articles and also has >30 issued or pending patents. Recently Weiwen and his colleague have developed the HDC (Hsp90-inhibitor Drug Conjugates) platform technology which has tremendous potential in creating an exciting, new class of anti-cancer therapies.

Prior to joining Synta in 2000, Dr. Ying was a postdoctoral fellow at SUNY Stony Brook and Yale University. He obtained Ph.D. in Organic Chemistry from Clemson University and M.S. from Shanghai Institute of Organic Chemistry, Chinese Academy of Science. He received his undergraduate degree from Zhongshan University in Guangzhou, China.

**Presentation Title:** HDC (Hsp90-Inhibitor Drug Conjugates): An Exciting and New Platform Technology in Oncology Drug Development.



**Jonathan J. Fleming, M.P.A.**

Managing General Partner, Boston, MA

Jonathan is the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston, Massachusetts and Seoul, Korea. He is a General Partner of the Korea-Seoul Life Science Fund.

Mr. Fleming has been in the investment business for over twenty seven years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Mr. Fleming is a director of several private companies including Dicerna Pharmaceuticals, Lab Partners, Greenlight and Railrunner. He is also a director of Leerink Swann, a Boston based investment bank specializing in healthcare companies. In addition, Mr. Fleming is a Senior Lecturer at the MIT Sloan School of Business, a Lecturer at the Harvard Medical School, a Trustee of the Museum of Science in Boston, and a Member of the Board of NEHI, a healthcare oriented think tank and policy advocacy group. Mr. Fleming is on the Scientific Advisory Board of the Massachusetts Life Science Center, and is a member of the Barnett Institute Advisory Board as well as the Chancellor's Commercialization Advisory Board of the University of Texas System. Mr. Fleming holds a Master's degree in Public Administration from Princeton University and a Bachelor of Arts degree from the University of California, Berkeley.



**David Xie, Ph.D., MBA**  
Associate, Oliver Wyman, Boston, MA

David is currently an associate with the healthcare practice at Oliver Wyman, a management consulting firm. Prior to joining Oliver Wyman, David served as the China advisor to SV Life Sciences Adviser, a healthcare focused venture capital fund based in Boston.

David's previous industry operating experience includes both work at Arch Venture Partners to finance and grow seed-stage life science companies, and 4 years at Helicos BioSciences to develop a next-generation DNA sequencing technology.

David has a PhD in Biophysics from the University of Chicago and an MBA from the MIT Sloan School of Management.



**Katherine Bowdish, Ph.D.**  
Vice President and Head of Sunrise, Sanofi , Cambridge, MA



**Xin Huang, M.D., Ph.D.**  
Healthcare Partner, Suzhou Cowin Venture Capital, Beijing, China.

Xin is a partner of Suzhou Cowin Venture Capital, which is the VC branch of Suzhou Venture Group, one of the largest venture groups in mainland China. Xin is in charge of Cowin Venture's investment in healthcare sector, mainly covering drug development, medical equipment, IVD, as well as basic life sciences. Dr. Huang's healthcare related experience began while a medical student at Peking Union Medical College in Beijing, where he earned his M.D. in 2003. Xin subsequently came to the east coast and earned his Ph.D. in Pharmacology from School of Medicine in Johns Hopkins University, where he conducted translational research in the Ludwig Center of Cancer Genetics and Biological Therapy. He then went back to China in 2009 and joined the Beijing office of Boston Consulting Group, serving as a management consultant to MNCs in healthcare sector. Later on he joined the venture capital community in China by taking the position of senior investment manager in Omaha Capital China before he finally took his current position in Cowin Venture in year 2012.



**Linda Ji, J.D., LL.M.**  
Partner, Nixon Peabody, Boston, MA

Linda is a partner in Nixon Peabody's Global Business and Transaction Practice and China Practice Groups. Linda has extensive experience in business transactions, with a specialty in cross-border corporate and technology transactions.

Having a deep understanding and knowledge of business transactions in both the U.S. and China and legal and cultural differences between the two countries, Linda counsels clients in a variety of industries, including consumer goods, high-tech, and life sciences, in the following areas:

U.S. companies doing business in China, including deal structuring, choice of entity, joint ventures, wholly foreign owned enterprises (WFOEs), acquisitions, regulatory filings, IP protection, and profits repatriation, as well as strategic alliances, manufacturing, distribution and licensing arrangements. Chinese companies setting up presence and expanding their operations in the U.S., including entry strategies, corporate and tax structuring, technology licensing, mergers and acquisitions, and raising capital through securities offerings.

Linda has advised both privately and publicly held companies in the U.S. (ranging from start-ups to *Fortune* 100 companies) in connection with company setup, private equity and venture capital financings, mergers and acquisitions, private placement of securities, IPOs and secondary public offerings of securities, as well as public company reporting and securities law compliance.



**Deqiang Niu, Ph.D.**  
Director of Medicinal Chemistry, Celgene Avilomics Research, Inc., Bedford, MA.

Deqiang is currently director of medicinal chemistry at Celgene Avilomics Research in Bedford, Massachusetts. His responsibility is overseeing the medicinal chemistry group research activities and maintaining a vigorous discovery pipeline. Deqiang obtained his B.S. and M.S. degrees from Peking University in the early 1990's. He continued his graduate study in organic chemistry at New York University and earned his Ph.D. in 1999. Dr. Niu then moved to Columbia University and completed his postdoctoral training with Professor Gilbert Stork working on the total synthesis of Quinine.

Deqiang started his biopharmaceutical career in Boston/Cambridge area in early 2001. Before his current position, he had worked at Enanta pharmaceuticals, Biogen Idec, and Avila Therapeutics for the past decade and with increased responsibility. Deqiang's drug discovery experience covers infectious, oncology and autoimmune diseases. The molecular targets of interest include proteases, kinases, protein synthesis and targeted covalent inhibitors for many other protein targets. He has presented, published and patented extensively in the medicinal chemistry area.

**Taiping Chen, Ph.D.**

Vice President, In Vivo Pharmacology, Viva Biotech, Shanghai, China

Taiping is leading Viva In vivo pharmacology (V-invivo) team aiming to offer world class CRO service to drug discovery clients around the world. Prior to joining Viva, Dr. Chen was VP of Translational Oncology at Crownbio (CRO). He led a team of 130 people offering unique and high quality cancer pharmacology, PDX (patient-derived xenograft) pharmacology, and biomarker service platforms. Dr. Chen was the leader to build a Biomarker Team at ArQule, a biotech company dedicated to the discovery and development of targeted anticancer therapeutics. In combination with Phase I clinical biomarker strategy, ARQ-197 has been successfully moved to Phase II and current Phase III trials. Before joining ArQule, he was associate director at Wood Hudson Cancer Research Lab (WHCRL) and worked on clinical biomarkers in conjunction with Lilly's target validation team. Dr. Chen received his DVM equivalent in Veterinary School, Shanxi Agricultural University in China. He received M.S. degree of Immunology at the National Control Center of Veterinary Medicine, Beijing, China. Dr. Chen earned his Ph.D. in Cancer Genetics from University of Texas MD Anderson Cancer Center and completed his postdoctoral research at Yale University School of Medicine. Dr. Chen has authored more than 60 abstracts and publications.

**Discussion Title:** PDX model for mimicking phase II clinical trial

**George Shi, Ph.D.**

Chief Scientific Officer, Anichem, Inc., North Brunswick, NJ

**Mohan Thiruvazhi, Ph.D.**

Director of Business Development, GVK BIO, San Diego, CA

Mohan Thiruvazhi is currently a Director of Business Development at GVK BIO and heads Key Accounts and manages East Coast territory. Prior to GVK BIO, he cofounded Incedis Therapeutics which provided Medicinal Chemistry consulting and managed discovery outsourcing for its clients. Mohan spent 6 years at ChemBridge Research Labs (CRL) where he built and headed the Chemistry Research department at CRL in San Diego which provided highly effective outsourcing support to clients. As a member of the Steering Group Committee, he co-chaired the Chemical Working Group and the Library Idea Committees for a 5 year/\$100MM file enrichment collaboration with a large pharma company. Prior to joining Chembridge, Mohan was a Senior Scientist At Abbott Lab in Chicago conducting synthetic chemistry in support of diagnostic products in cardiovascular and nutritional disorders. He obtained a doctoral degree in Synthetic Chemistry from SUNY (Albany) followed by postdoctoral stints at University of Pittsburgh and Research Triangle Institute.

**Tiansheng Wang, Ph.D.**

Research Fellow, Vertex Pharmaceuticals Inc., Cambridge, MA

Tiansheng has been a medicinal chemist at Vertex for 13 years. At Vertex, Tiansheng had involved in multiple drug discovery programs including antibacterial, anti-inflammation and anti-cancer lead optimization projects. He was the Cambridge Early Research Chemistry head working with biologists for new drug targets, one of such efforts lead to a novel mechanism based anti-flu drug candidate. Tiansheng currently serves as the chemistry head for a fully outsourced antibacterial project, managing 14 chemistry FTEs. Before Vertex, Tiansheng had worked at Novartis and Nitromed. He did postdoctoral research work at University Vermont in indole alkaloid total synthesis. He had a BS from Zhengzhou University and a PhD. from Nankai University.

**Sherry Yu, Ph. D., MBA**

Director of Global Business Development, Sundia MediTech, Boston, MA.

Dr. Sherry Yu previously had worked at Analog Devices and Wyeth BioPharma with various assignments in process development, engineering operations and project management. She earned a Bachelor's Degree in Chemistry from University of Science and Technology of China, a Master's Degree in Chemistry and a Ph. D. in Chemical Engineering both from University of Michigan. In 2011, she received a Master's Degree in Business Administration from Massachusetts Institute of Technology's Sloan School of Management.

**Discussion Title:** Sundia: Your Partner for Drug Discovery and Development!

**Libing Yu, Ph.D.**

Founder, CEO and Board Director of Alputon (Shanghai) PharmaTech Co. Ltd., Shanghai, China

Libing is founder, CEO and board director of Alputon (Shanghai) PharmaTech Co. Ltd, which has been providing world class chemistry services to global pharmaceutical and biotech companies since 2007. Prior to founding Alputon, Libing was director of chemistry at ArQule Inc., Woburn, MA, leading discovery programs, technology development and collaborations with pharmaceutical partners. Libing did his postdoctoral research in the area of carbohydrate chemistry and medicinal chemistry at University of Miami, Miami, Florida, after he was awarded Ph.D. in Organic Chemistry at Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. Libing has published more than 40 research papers and patents.

**Jin Zhao, Ph.D.**

Senior Scientist, Process Chemistry, Genzyme, Waltham, MA.

Jin received his Ph.D in organic synthesis from University Wales, Swansea, UK and did his postdoctoral training in organic synthesis at Bristol University in UK and photo-chemistry at Southern Mississippi University. Jin previously worked at Biogen, Prime

Organics, Inotech pharmaceuticals and currently at Genzyme, Sanofi (after Genzyme merged with Sanofi) as a process chemist, experienced working under cGMP condition. His current roles include leading his team in chemical process development, chemical synthesis and process optimization; process impurities and metabolites synthesis.

Jin also involves in Boston Chinese community activities. He is currently a management team member of OCEAN (Overseas Chinese-American Entrepreneurs Association) participated in and organized many local Chinese events.

SponsorsMorgan StanleyAlputon Inc.

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potentials. CABA is a volunteer-based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves for its members.

**CABA Mission:**

- *To promote science, technology, and business collaboration in biotech/pharmaceutical industry*
- *To build and maintain a platform through cohesive scientific, professional, and cultural connection that provides high quality service*
- *To facilitate networking among scientists, professionals, and entrepreneurs in academia, biotech/pharmaceutical industry and regulatory agencies*
- *To embrace advancement of science and commercialization of innovation that will benefit human health*
- *To foster collaborations between the United States and China for the development of better biotech/pharmaceutical therapeutics*